Get the Stockscreener App
22.21
5.33%
-1.25
After Hours:
22.23
0.02
+0.09%
Jade Biosciences Inc stock is traded at $22.21, with a volume of 372.12K.
It is down -5.33% in the last 24 hours and down -12.49% over the past month.
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
See More
Previous Close:
$23.46
Open:
$23.56
24h Volume:
372.12K
Relative Volume:
0.67
Market Cap:
$1.10B
Revenue:
-
Net Income/Loss:
$-91.76M
P/E Ratio:
-4.0722
EPS:
-5.4541
Net Cash Flow:
$-94.89M
1W Performance:
-4.90%
1M Performance:
-12.49%
6M Performance:
+85.08%
1Y Performance:
+203.42%
1-Day Range:
$22.16
$23.91
1-Week Range:
$20.93
$24.00
52-Week Range:
$6.565
$28.00
Jade Biosciences Inc Stock (JBIO) Company Profile
Name
Jade Biosciences Inc
Sector
Industry
Phone
(781) 312-3013
Address
221 CRESCENT ST., WALTHAM
Compare JBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
22.21 | 1.16B | 0 | -91.76M | -94.89M | -5.4541 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Initiated | BTIG Research | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jun-16-25 | Upgrade | Guggenheim | Neutral → Buy |
| May-07-25 | Initiated | Wedbush | Outperform |
| May-05-25 | Initiated | Stifel | Buy |
| May-02-25 | Initiated | TD Cowen | Buy |
| Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-25-24 | Resumed | Jefferies | Buy |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Jul-26-21 | Initiated | Cowen | Outperform |
| Jul-26-21 | Initiated | Evercore ISI | Outperform |
| Jul-26-21 | Initiated | Jefferies | Buy |
| Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Jade Biosciences Inc Stock (JBIO) Latest News
Jade Biosciences Inc. (JBIO) Q1 2026 Earnings: EPS Miss Amid Continued Pre‑Revenue PhaseHot Momentum Watchlist - Newser
Jade Biosciences Inc. (JBIO) Q1 2026 Earnings: Clinical‑stage Biotech Misses Consensus as Cash Burn AcceleratesLive Trade Sharing - Newser
Jade Biosciences Inc. (JBIO) Holds Steady as Price Consolidates Near Key ResistanceCatalyst Driven Stocks - Newser
Jade Biosciences (JBIO) price target increased by 16.48% to 26.14 - MSN
[EFFECT] Jade Biosciences, Inc. SEC Filing - Stock Titan
Jade Biosciences IncProspectus filed for resale of up to 39,542,339 shares by selling stockholdersSEC filing - marketscreener.com
Jade Biosciences (JBIO) Declines -4.19% Amid Market Weakness 2026-05-15Expert Breakout Alerts - newser.com
Jade Biosciences (JBIO) Q1 2026 Disappoints — EPS $-0.57 Below $-0.49 ViewsForward Guidance - newser.com
Janus Henderson (JBIO) discloses 3,105,669-share, 6.3% holding in Jade Biosciences - Stock Titan
Jade Biosciences(JBIO) Stock Options Chain | Quotes & News - Moomoo
Jade Biosciences (JBIO) Q1 2026 Earnings Miss by Significant: Key TakeawaysHealthcare Earnings Report - Newser
H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Jade Biosciences Price Target Raised to $34.00/Share From $24.00 by Wedbush - Moomoo
Jade Biosciences (NASDAQ:JBIO) Given New $34.00 Price Target at Wedbush - MarketBeat
Guggenheim Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $32 - Moomoo
Jade Biosciences (NASDAQ:JBIO) Cut to "Sell" at Wall Street Zen - MarketBeat
Analyst Reiterates Buy on Jade Biosciences as JADE101 Data and Multi-Asset Pipeline Catalysts Approach - TipRanks
Jade Biosciences: Buy Rating Reiterated on Strong Cash Runway, JADE101 Differentiation, and Unchanged $24 Price Target - TipRanks
TD Cowen Maintains Jade Biosciences(JBIO.US) With Buy Rating - Moomoo
Stifel Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Jade Biosciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Why Jade Biosciences (JBIO) looks attractive at current levels (Edges Lower) 2026-05-07Investment Community Signals - Newser
Jade Biosciences Inc may offer and sell up to $600 million of securitiesSEC filing - marketscreener.com
[S-3] Jade Biosciences, Inc. Shelf Registration Statement - Stock Titan
Jade Biosciences (NASDAQ: JBIO) posts $40.4M Q1 loss, ATM up to $200M - Stock Titan
Jade Biosciences (JBIO) ramps R&D with $40.4M loss and $311M cash - Stock Titan
Jade Biosciences (NASDAQ: JBIO) details Q1 2026 loss and cash - Stock Titan
2 small-cap stocks with big potential to buy under $30 - MSN
BRIEF-Jade Biosciences, Inc Q1 Cash & Investments USD 311.3 Million - TradingView
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update - ChartMill
JBIO SEC FilingsJade Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Jade Biosciences Reshapes Clinical Leadership As Valuation Debate Persists - Sahm
2 Small-Cap Stocks With Big Potential to Buy Under $30 - Barchart.com
Jade Biosciences (NASDAQ:JBIO) Stock Price Down 9.6%Here's What Happened - MarketBeat
What is HC Wainwright's Forecast for JBIO FY2030 Earnings? - MarketBeat
Jade Biosciences (NASDAQ: JBIO) outlines 2026 director votes, auditor and jury waiver - Stock Titan
Jade Biosciences (NASDAQ:JBIO) Sets New 1-Year HighHere's What Happened - MarketBeat
FY2028 Earnings Forecast for JBIO Issued By HC Wainwright - MarketBeat
Jade Biosciences stock hits 52-week high at 27.44 USD By Investing.com - Investing.com South Africa
Jade Biosciences (JBIO) price target increased by 10.24% to 28.82 - MSN
BlackRock (NYSE: JBIO) reports 2.3M JADE stake, 4.7% disclosed - Stock Titan
Jade Biosciences stock hits 52-week high at 27.44 USD - Investing.com
Jade Biosciences stock price target raised to $45 by H.C. Wainwright - Investing.com Canada
H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $45 - Moomoo
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Jade Biosciences, Inc. (NASDAQ:JBIO) Short Interest Update - MarketBeat
Jade Biosciences, Inc. Grants Equity Award to New Chief Medical Officer Edward R. Conner, M.D. - Quiver Quantitative
Jade Biosciences Inc Stock (JBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):